Generation Bio (NASDAQ:GBIO) Rating Reiterated by Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Generation Bio (NASDAQ:GBIO) in a research report released on Thursday, Benzinga reports. They currently have a $10.00 target price on the stock.

Separately, Wedbush restated an outperform rating and issued a $5.00 target price on shares of Generation Bio in a research note on Tuesday, May 14th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Generation Bio has an average rating of Hold and an average price target of $8.00.

Generation Bio Price Performance

Shares of GBIO stock opened at $2.35 on Thursday. Generation Bio has a 12 month low of $0.86 and a 12 month high of $5.50. The firm has a market capitalization of $156.34 million, a P/E ratio of -0.92 and a beta of 2.83. The company’s fifty day moving average price is $2.85 and its two-hundred day moving average price is $2.91.

Generation Bio (NASDAQ:GBIO) last issued its quarterly earnings data on Monday, May 13th. The company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.76). The firm had revenue of $4.06 million during the quarter, compared to analyst estimates of $3.02 million. Generation Bio had a negative return on equity of 82.33% and a negative net margin of 1,696.87%. On average, sell-side analysts anticipate that Generation Bio will post -1.68 EPS for the current year.

Institutional Investors Weigh In On Generation Bio

Institutional investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD grew its position in shares of Generation Bio by 28.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,878,361 shares of the company’s stock valued at $36,136,000 after buying an additional 1,952,187 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of Generation Bio by 113.9% during the 1st quarter. Acadian Asset Management LLC now owns 479,835 shares of the company’s stock valued at $1,952,000 after buying an additional 255,468 shares during the last quarter. Bellevue Group AG grew its position in shares of Generation Bio by 6.8% during the 1st quarter. Bellevue Group AG now owns 3,861,575 shares of the company’s stock valued at $15,717,000 after buying an additional 244,495 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Generation Bio during the 1st quarter valued at about $74,000. Finally, Los Angeles Capital Management LLC grew its position in shares of Generation Bio by 38.4% during the 1st quarter. Los Angeles Capital Management LLC now owns 381,661 shares of the company’s stock valued at $1,553,000 after buying an additional 105,827 shares during the last quarter. Institutional investors and hedge funds own 95.22% of the company’s stock.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.